This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| proper | frequency |
|---|---|
| COVID-19 | 171116 |
| SARS | 85680 |
| CoV-2 | 59452 |
| China | 30419 |
| Coronavirus | 18321 |
| Health | 17593 |
| Wuhan | 17072 |
| CT | 15587 |
| ACE2 | 12953 |
| March | 11597 |
| Disease | 10388 |
| CoV | 10287 |
| ICU | 10141 |
| PCR | 9403 |
| Table | 9186 |
| April | 8666 |
| Fig | 8609 |
| MERS | 7297 |
| RNA | 7193 |
| Italy | 7077 |
| United | 6786 |
| World | 6693 |
| • | 6657 |
| sha | 6618 |
| J | 6554 |
| May | 6509 |
| RT | 6429 |
| ARDS | 6364 |
| IL-6 | 6304 |
| el | 6205 |
| PPE | 5928 |
| COVID | 5877 |
| States | 5856 |
| T | 5644 |
| CC | 5641 |
| DOI | 5542 |
| Covid-19 | 5359 |
| Organization | 5356 |
| US | 5301 |
| New | 5125 |
| UK | 4881 |
| National | 4668 |
| medRxiv | 4580 |
| Clinical | 4562 |
| BY | 4546 |
| January | 4521 |
| C | 4496 |
| Hospital | 4491 |
| India | 4371 |
| February | 4271 |
| University | 4203 |
| los | 4188 |
| CI | 4101 |
| Care | 4009 |
| ND | 3936 |
| II | 3918 |
| Novel | 3890 |
| NC | 3882 |
| June | 3838 |
| HIV | 3822 |
| Society | 3724 |
| Pandemic | 3600 |
| Control | 3520 |
| mg | 3465 |
| meta | 3396 |
| USA | 3368 |
| S | 3348 |
| East | 3330 |
| Association | 3265 |
| South | 3242 |
| HCQ | 3232 |
| Prevention | 3136 |
| Medical | 3121 |
| York | 3118 |
| Research | 3051 |
| December | 3048 |
| un | 2998 |
| M | 2991 |
| Korea | 2979 |
| Middle | 2944 |
| Syndrome | 2937 |
| Figure | 2873 |
| nan | 2832 |
| Center | 2826 |
| A | 2823 |
| Africa | 2745 |
| July | 2667 |
| Study | 2621 |
| remdesivir | 2591 |
| CDC | 2584 |
| Respiratory | 2572 |
| Review | 2564 |
| American | 2553 |
| WHO | 2552 |
| International | 2535 |
| Patients | 2532 |
| Europe | 2518 |
| IFN | 2475 |
| Spain | 2467 |
| del | 2461 |
| Treatment | 2449 |
| las | 2407 |
| L | 2406 |
| Hubei | 2378 |
| U.S. | 2376 |
| para | 2304 |
| CRP | 2271 |
| ED | 2264 |
| Public | 2239 |
| TNF | 2233 |
| Data | 2225 |
| Department | 2208 |
| D | 2202 |
| Ebola | 2198 |
| Medicine | 2186 |
| Pneumonia | 2185 |
| con | 2087 |
| Analysis | 2068 |
| M. | 2055 |
| France | 2035 |
| Emergency | 2035 |
| Group | 2032 |
| TMPRSS2 | 2021 |
| Wang | 1978 |
| European | 1973 |
| H1N1 | 1964 |
| Institute | 1959 |
| Germany | 1950 |
| hydroxychloroquine | 1912 |
| City | 1909 |
| Chinese | 1897 |
| Hydroxychloroquine | 1897 |
| Impact | 1879 |
| IgM | 1866 |
| Risk | 1863 |
| Global | 1859 |
| CD4 | 1850 |
| IgG | 1845 |
| B | 1831 |
| Committee | 1824 |
| IQR | 1800 |
| America | 1793 |
| Brazil | 1791 |
| tocilizumab | 1768 |
| azithromycin | 1761 |
| covid-19 | 1734 |
| Hong | 1731 |
| Management | 1727 |
| Human | 1726 |
| Lancet | 1716 |
| α | 1706 |
| Singapore | 1704 |
| College | 1693 |
| Li | 1680 |
| S. | 1671 |
| Report | 1667 |
| CD8 | 1653 |
| Infection | 1644 |
| FDA | 1635 |
| Kong | 1621 |
| AI | 1605 |
| Social | 1598 |
| September | 1590 |
| R | 1587 |
| ECMO | 1586 |
| pacientes | 1578 |
| una | 1574 |
| CoV-1 | 1559 |
| August | 1557 |
| S1 | 1553 |
| en | 1551 |
| J. | 1547 |
| Iran | 1526 |
| Remdesivir | 1524 |
| Province | 1520 |
| ritonavir | 1513 |
| VTE | 1512 |
| General | 1510 |
| Ministry | 1506 |
| COPD | 1494 |
| N95 | 1467 |
| State | 1461 |
| System | 1456 |
| N | 1456 |
| Infectious | 1450 |
| Use | 1447 |
| Zhang | 1438 |
| Diseases | 1435 |
| C. | 1433 |
| Characteristics | 1431 |
| Science | 1430 |
| Patient | 1430 |
| La | 1426 |
| AKI | 1426 |
| preprint | 1420 |
| England | 1419 |
| 1404 | |
| COVID‐19 | 1401 |
| Influenza | 1393 |
| IBD | 1368 |
| Supplementary | 1365 |
| Canada | 1356 |
| Japan | 1354 |
| Chen | 1353 |
| Commission | 1347 |
| NK | 1343 |
| BCG | 1341 |
| Angiotensin | 1341 |
| por | 1337 |
| Development | 1331 |
| Virus | 1322 |
| Cancer | 1320 |
| BMI | 1317 |
| Healthcare | 1315 |
| Med | 1301 |
| Government | 1294 |
| Case | 1293 |
| F | 1280 |
| lymphopenia | 1273 |
| Centers | 1273 |
| Chest | 1272 |
| North | 1267 |
| L. | 1236 |
| CSF | 1236 |
| CoV2 | 1231 |
| Transmission | 1202 |
| como | 1198 |
| Liu | 1184 |
| Drug | 1181 |
| Americans | 1177 |
| Republic | 1163 |
| Asia | 1159 |
| Australia | 1157 |
| Response | 1154 |
| U | 1141 |
| NHS | 1132 |
| Mental | 1128 |
| Journal | 1122 |
| 1121 | |
| Outcomes | 1121 |
| CNS | 1118 |
| CXR | 1111 |
| CQ | 1104 |
| IV | 1091 |
| GI | 1090 |
| CFR | 1079 |
| Saudi | 1077 |
| Evaluation | 1077 |
| Centre | 1074 |
| R. | 1073 |
| Chloroquine | 1068 |
| ACE | 1058 |
| RBD | 1054 |
| Food | 1051 |
| I | 1047 |
| ± | 1041 |
| Appendix | 1040 |
| lopinavir | 1036 |
| October | 1032 |
| LDH | 1030 |
| GGO | 1029 |
| PE | 1029 |
| Network | 1024 |
| E | 1024 |
| COV-2 | 1018 |
| Cov-2 | 1014 |
| der | 1009 |
| IL-10 | 1009 |
| Model | 1008 |
| Lung | 999 |
| Intensive | 999 |
| Lombardy | 997 |
| Epidemiology | 997 |
| Taiwan | 994 |
| ACE-2 | 993 |
| Arabia | 992 |
| Guidelines | 985 |
| SIR | 978 |
| Commons | 972 |
| < | 970 |
| Tocilizumab | 968 |
| Survey | 966 |
| SPSS | 964 |
| Creative | 962 |
| Bangladesh | 960 |
| PubMed | 959 |
| du | 958 |
| Pakistan | 958 |
| Assessment | 954 |
| doc_id | 945 |
| Kingdom | 945 |
| Ethics | 939 |
| Trial | 937 |
| D. | 936 |
| es | 936 |
| 8) | 935 |
| Administration | 934 |
| People | 930 |
| Meta | 929 |
| CVD | 917 |
| Yang | 913 |
| Ang | 913 |
| CNN | 912 |
| des | 909 |
| LUS | 901 |
| Dr. | 898 |
| E. | 896 |
| Diagnosis | 895 |
| MRI | 893 |
| S2 | 892 |
| Rapid | 873 |
| CoVs | 865 |
| Acute | 865 |
| Foundation | 864 |
| Scale | 861 |
| Team | 859 |
| Nature | 850 |
| HCWs | 847 |
| El | 847 |
| Washington | 841 |
| Detection | 833 |
| DIC | 833 |
| doi | 832 |
| Wu | 829 |
| Safety | 824 |
| Heart | 818 |
| PD | 817 |
| MS | 816 |
| Board | 814 |
| Se | 809 |
| Index | 805 |
| Fisher | 804 |
| A. | 803 |
| Imaging | 801 |
| G | 799 |
| Huang | 798 |
| Community | 792 |
| COVID19 | 792 |
| B. | 787 |
| Time | 785 |
| AUC | 785 |
| West | 785 |
| III | 782 |
| Critical | 778 |
| Children | 776 |
| Unit | 775 |
| disease | 774 |
| Systematic | 774 |
| PTSD | 773 |
| London | 773 |
| le | 769 |
| P. | 768 |
| Outbreak | 765 |
| RAS | 760 |
| Council | 759 |
| K. | 758 |
| Viral | 756 |
| IgA | 754 |
| PM | 751 |
| Springer | 745 |
| IL-1 | 745 |
| Guidance | 743 |
| interleukin-6 | 741 |
| Services | 741 |
| Effect | 740 |
| CRS | 740 |
| K | 739 |
| Corona | 736 |
| Anxiety | 735 |
| Therapy | 733 |
| Zhou | 732 |
| GM | 729 |
| Nigeria | 728 |
| Hospitalized | 725 |
| X | 724 |
| Pulmonary | 723 |
| les | 722 |
| Sciences | 721 |
| First | 720 |
| ECG | 720 |
| ELISA | 715 |
| County | 712 |
| ARB | 712 |
| Coronaviruses | 710 |
| γ | 708 |
| November | 699 |
| SD | 698 |
| H. | 697 |
| Lopinavir | 692 |
| HCoV | 690 |
| kg | 690 |
| Beijing | 689 |
| | | 684 |
| Cardiovascular | 683 |
| Associated | 682 |
| Radiology | 680 |
| HCW | 680 |
| su | 679 |
| MD | 679 |
| ST | 678 |
| Central | 676 |
| von | 674 |
| LMWH | 671 |
| Sweden | 664 |
| G. | 664 |
| Cardiac | 664 |
| Factors | 659 |
| Shanghai | 657 |
| Kawasaki | 657 |
| Information | 655 |
| AIDS | 653 |
| Systems | 651 |
| English | 651 |
| De | 648 |
| ID | 644 |
| Cox | 642 |
| mL | 641 |
| TB | 641 |
| Cell | 641 |
| monocyte | 640 |
| Article | 638 |
| Early | 636 |
| Clin | 635 |
| N. | 631 |
| Mann | 631 |
| Times | 629 |
| Distress | 627 |
| PA | 621 |
| casos | 618 |
| van | 617 |
| Technology | 616 |
| Northern | 616 |
| MIS | 616 |
| Adults | 616 |
| − | 614 |
| series | 613 |
| Recommendations | 613 |
| California | 609 |
| Practice | 607 |
| ICUs | 606 |
| Covid | 605 |
| Service | 603 |
| mid | 601 |
| Office | 601 |
| Cochrane | 600 |
| Whitney | 595 |
| Director | 594 |
| Region | 591 |
| NLR | 591 |
| Laboratory | 591 |
| Statistics | 588 |
| Netherlands | 588 |
| EC | 588 |
| Los | 587 |
| Efficacy | 586 |
| HR | 585 |
| F. | 585 |
| β | 582 |
| OC43 | 582 |
| se | 581 |
| ROC | 581 |
| 581 | |
| COVID-2019 | 580 |
| multicentre | 579 |
| au | 577 |
| Immune | 577 |
| Education | 576 |
| Program | 575 |
| EU | 575 |
| Receptor | 572 |
| Statistical | 570 |
| Y | 570 |
| Surgery | 569 |
| Epidemic | 567 |
| AST | 566 |
| Institutional | 562 |
| NIV | 556 |
| OR | 555 |
| Lee | 555 |
| Workers | 554 |
| Xu | 552 |
| Hopkins | 551 |
| Stress | 550 |
| Economic | 548 |
| Population | 546 |
| Likert | 544 |
| JAK | 543 |
| SEIR | 543 |
| Pediatric | 538 |
| Turkey | 537 |
| Italian | 537 |
| African | 535 |
| sobre | 533 |
| pandemia | 532 |
| RdRp | 532 |
| High | 532 |
| Quality | 531 |
| CO | 531 |
| Union | 525 |
| Protection | 525 |
| Psychological | 523 |
| ACEI | 521 |
| Guillain | 520 |
| RAAS | 520 |
| Studies | 520 |
| CKD | 519 |
| LPV | 517 |
| Int | 516 |
| Infections | 516 |
| Mexico | 514 |
| Ill | 514 |
| HLA | 513 |
| Agency | 512 |
| Chi | 511 |
| Zika | 507 |
| Severe | 507 |
| Act | 507 |
| Pearson | 506 |
| Inc. | 506 |
| STEMI | 505 |
| Spike | 505 |
| DVT | 504 |
| Findings | 503 |
| Attribution | 502 |
| ER | 502 |
| ou | 501 |
| T. | 501 |
| lo | 500 |
| Policy | 500 |
| st | 499 |
| Phase | 499 |
| TCZ | 498 |
| Helsinki | 498 |
| EEG | 498 |
| author(s | 497 |
| IBM | 497 |
| Features | 497 |
| Declaration | 496 |
| H | 495 |
| Scientific | 495 |
| GAD-7 | 492 |
| sera | 491 |
| School | 490 |
| Testing | 489 |
| R0 | 489 |
| Protein | 489 |
| News | 489 |
| Kim | 489 |
| NIH | 487 |
| Dis | 487 |
| enfermedad | 486 |
| más | 485 |
| David | 485 |
| Academy | 485 |
| Project | 483 |
| Open | 482 |
| Israel | 482 |
| Note | 480 |
| San | 479 |
| PCT | 479 |
| i | 478 |
| John | 477 |
| Access | 477 |
| ALT | 477 |
| Zhao | 475 |
| Stroke | 473 |
| uso | 470 |
| κB | 469 |
| Bank | 469 |
| Task | 468 |
| DM | 466 |
| PHQ-9 | 466 |
| Cardiology | 465 |
| PRISMA | 464 |
| IL-8 | 464 |
| Cronbach | 464 |
| Azithromycin | 464 |
| HIV-1 | 463 |
| ACS | 463 |
| health | 462 |
| TCM | 461 |
| IL-1β | 461 |
| Neutrophil | 460 |
| MSC | 458 |
| Statement | 457 |
| Support | 456 |
| Chronic | 455 |
| NL63 | 454 |
| Crisis | 454 |
| ROS | 452 |
| PT | 452 |
| GDP | 450 |
| Eq | 448 |
| infección | 447 |
| WBC | 447 |
| Aerosol | 447 |
| IU | 446 |
| chloroquine | 445 |
| Yu | 444 |
| Force | 444 |
| W. | 443 |
| Nations | 442 |
| IL-2 | 442 |
| da | 442 |
| Vietnam | 440 |
| ageusia | 440 |
| tratamiento | 439 |
| Life | 439 |
| Digital | 439 |
| riesgo | 438 |
| Reporting | 438 |
| puede | 436 |
| Johns | 436 |
| Effectiveness | 436 |
| estudio | 435 |
| Michael | 434 |
| Consensus | 434 |
| British | 432 |
| Accepted | 431 |
| Online | 431 |
| ser | 430 |
| china | 430 |
| RCT | 430 |
| Prediction | 430 |
| CoV. | 429 |
| SC | 428 |
| Austria | 428 |
| Zealand | 424 |
| QT | 424 |
| Cross | 424 |
| RA | 423 |
| Oncology | 422 |
| Kerala | 422 |
| Based | 422 |
| Learning | 421 |
| Molecular | 421 |
| White | 421 |
| Structure | 420 |
| Mortality | 420 |
| Expert | 420 |
| Ritonavir | 419 |
| Organisation | 419 |
| han | 418 |
| disease-2019 | 418 |
| Ireland | 418 |
| ng | 417 |
| entre | 417 |
| Questionnaire | 416 |
| Nepal | 416 |
| Arbidol | 416 |
| CPAP | 415 |
| Vero | 415 |
| NP | 414 |
| S3 | 413 |
| Dr | 412 |
| CA | 412 |
| ¼ | 411 |
| Epidemiological | 411 |
| Age | 411 |
| Res | 410 |
| IRB | 410 |
| Family | 409 |
| anakinra | 408 |
| inflammasome | 407 |
| association | 407 |
| Kenya | 407 |
| Antibody | 406 |
| Zhejiang | 405 |
| Post | 405 |
| Knowledge | 405 |
| Plasma | 404 |
| Surgeons | 402 |
| Spanish | 402 |
| IVIG | 402 |
| Q | 401 |
| Convalescent | 401 |
| Princess | 400 |
| Les | 400 |
| Working | 399 |
| RR | 399 |
| Sun | 398 |
| NF | 398 |
| Joint | 397 |
| ≤ | 397 |
| Deep | 396 |
| Vaccine | 395 |
| Switzerland | 395 |
| Surg | 395 |
| Royal | 395 |
| RSV | 395 |
| Tang | 394 |
| ML | 394 |
| Liver | 393 |
| DNA | 392 |
| Maria | 391 |
| Lin | 391 |
| Malaysia | 390 |
| Depression | 389 |
| Non | 388 |
| Summary | 388 |
| Potential | 386 |
| Cases | 386 |
| V. | 385 |
| Panel | 385 |
| Emerging | 385 |
| Black | 385 |
| Chicago | 384 |
| Cohort | 384 |
| Thrombosis | 383 |
| Randomized | 383 |
| Publisher | 383 |
| Lu | 383 |
| Le | 383 |
| CK | 383 |
| Abstract | 383 |
| CP | 382 |
| Diamond | 382 |
| Medicare | 382 |
| Al | 380 |
| IMV | 379 |
| IC | 378 |
| enoxaparin | 377 |
| Thoracic | 377 |
| Sci | 377 |
| Long | 376 |
| Trump | 375 |
| Trials | 375 |
| Rt | 375 |
| EMS | 375 |
| Air | 375 |
| President | 374 |
| mRNA | 373 |
| SAS | 373 |
| Johnson | 372 |
| King | 372 |
| Inhibitors | 371 |
| Security | 371 |
| P | 370 |
| Favipiravir | 370 |
| Zhu | 369 |
| Telemedicine | 368 |
| Shi | 368 |
| und | 367 |
| favipiravir | 367 |
| Supplemental | 366 |
| Latin | 366 |
| Thomas | 365 |
| Protocol | 364 |
| Madrid | 364 |
| Indian | 363 |
| Front | 363 |
| mit | 363 |
| Institutes | 363 |
| Cohen | 362 |
| Texas | 362 |
| Investigation | 361 |
| ALI | 361 |
| Personal | 360 |
| Y. | 359 |
| Parkinson | 359 |
| Anti | 359 |
| cas | 358 |
| Poisson | 358 |
| MM | 358 |
| Clinic | 358 |
| COV | 358 |
| Interim | 357 |
| Thailand | 357 |
| Paulo | 357 |
| bronchoalveolar | 356 |
| antiphospholipid | 356 |
| Alzheimer | 356 |
| mayor | 355 |
| _ | 355 |
| Kumar | 355 |
| V | 354 |
| Paris | 354 |
| IoT | 354 |
| Coronaviridae | 353 |
| Barré | 352 |
| Kidney | 352 |
| LAMP | 352 |
| Spearman | 352 |
| ARIMA | 351 |
| Application | 351 |
| Low | 350 |
| ABO | 350 |
| estudios | 349 |
| Registry | 348 |
| I. | 347 |
| Oxford | 346 |
| Jan | 346 |
| COVID- | 346 |
| vivo | 344 |
| Psychiatry | 343 |
| NY | 342 |
| Blood | 341 |
| Belgium | 340 |
| GBS | 339 |
| BALF | 338 |
| pandemic | 338 |
| Microsoft | 337 |
| Area | 336 |
| Interventions | 335 |
| paciente | 334 |
| Series | 334 |
| Seattle | 334 |
| analysis | 333 |
| Russia | 332 |
| Minister | 332 |
| Dynamics | 331 |
| Classification | 331 |
| Brain | 329 |
| Delhi | 329 |
| datos | 329 |
| EHR | 329 |
| mortalidad | 328 |
| Organ | 328 |
| Situation | 327 |
| Mechanisms | 327 |
| HLH | 327 |
| une | 326 |
| 326 | |
| HFNC | 325 |
| MAS | 324 |
| Engineering | 324 |
| Background | 324 |
| Transplant | 323 |
| Surveillance | 323 |
| UCI | 323 |
| qPCR | 323 |
| key | 322 |
| hs | 322 |
| Women | 322 |
| Observational | 322 |
| Diagnostic | 322 |
| HCV | 321 |
| Day | 321 |
| Kaplan | 321 |
| Wei | 320 |
| Preparedness | 320 |
| QTc | 319 |
| Wales | 318 |
| Sars | 318 |
| IL | 318 |
| Antiviral | 318 |
| License | 317 |
| general | 317 |
| −1 | 316 |
| Approach | 316 |
| Self | 316 |
| Surgical | 315 |
| Interleukin-6 | 315 |
| Mpro | 314 |
| Hu | 314 |
| Head | 314 |
| Federal | 314 |
| Toronto | 313 |
| Artificial | 313 |
| east | 312 |
| Smith | 312 |
| SARS‐CoV‐2 | 312 |
| DR | 312 |
| French | 311 |
| esta | 311 |
| Reviews | 310 |
| Guangdong | 310 |
| Telehealth | 309 |
| ClinicalTrials.gov | 309 |
| recomienda | 308 |
| ont | 307 |
| Shenzhen | 307 |
| Scopus | 307 |
| HCP | 306 |
| este | 305 |
| VA | 304 |
| Natural | 304 |
| Daily | 304 |
| MP | 303 |
| Ontario | 303 |
| min | 302 |
| Roche | 302 |
| Egypt | 302 |
| Census | 302 |
| à | 302 |
| sars | 301 |
| NT | 301 |
| Gene | 301 |
| 3D | 301 |
| Nutrition | 300 |
| Chan | 300 |
| CD3 | 300 |
| Singh | 300 |
| diagnóstico | 300 |
| Stata | 300 |
| Test | 299 |
| Failure | 299 |
| Xiao | 298 |
| EM | 298 |
| Van | 297 |
| Cheng | 297 |
| RV | 296 |
| días | 296 |
| Score | 296 |
| debe | 295 |
| Trends | 295 |
| Tongji | 295 |
| Guan | 295 |
| Framework | 295 |
| En | 295 |
| Material | 294 |
| Student | 294 |
| Ethiopia | 293 |
| HKU1 | 293 |
| Yan | 292 |
| Design | 292 |
| Enzyme | 291 |
| Daegu | 291 |
| Denmark | 290 |
| Activity | 290 |
| Discovery | 290 |
| E6 | 290 |
| Version | 289 |
| Methods | 289 |
| ENT | 289 |
| NLRP3 | 288 |
| Cao | 288 |
| Environment | 288 |
| UN | 288 |
| OD | 288 |
| coronavirus | 288 |
| × | 287 |
| ward | 287 |
| SVM | 287 |
| Nursing | 287 |
| MV | 287 |
| Level | 287 |
| Biobank | 287 |
| Pacific | 286 |
| PD-1 | 286 |
| Milan | 286 |
| CRISPR | 286 |
| Guo | 285 |
| HA | 285 |
| Robert | 284 |
| Guideline | 284 |
| DC | 284 |
| pH | 284 |
| Canadian | 283 |
| BMJ | 283 |
| ANOVA | 283 |
| Protective | 283 |
| eine | 283 |
| Portugal | 282 |
| Intelligence | 282 |
| LV | 281 |
| LPS | 280 |
| Jordan | 280 |
| Activation | 280 |
| HRCT | 279 |
| Carlo | 279 |
| Regional | 279 |
| Meier | 279 |
| Monitoring | 279 |
| nd | 278 |
| dans | 278 |
| Renin | 278 |
| Net | 278 |
| Michigan | 278 |
| H5N1 | 277 |
| Environmental | 277 |
| DD | 277 |
| Child | 276 |
| Asian | 275 |
| Daniel | 275 |
| Illness | 275 |
| hepatitis | 275 |
| ventilación | 275 |
| medidas | 275 |
| Wilcoxon | 274 |
| Identification | 274 |
| Western | 273 |
| Trust | 273 |
| Rep | 273 |
| Injury | 273 |
| HF | 273 |
| Estimation | 273 |
| Type | 272 |
| PM2.5 | 272 |
| MA | 272 |
| Dexamethasone | 272 |
| Guardian | 271 |
| KD | 271 |
| sarilumab | 270 |
| Spread | 270 |
| Severity | 270 |
| HBV | 270 |
| Equipment | 270 |
| SOC | 269 |
| Plan | 269 |
| IPC | 269 |
| TM | 268 |
| SLE | 268 |
| Networks | 268 |
| Consortium | 268 |
| CBT | 268 |
| IL-17 | 267 |
| Neural | 267 |
| kcal | 267 |
| multiorgan | 267 |
| Geneva | 266 |
| control | 265 |
| STAT3 | 265 |
| Initiative | 265 |
| SpO2 | 264 |
| Paul | 264 |
| Las | 264 |
| Editor | 264 |
| Computing | 264 |
| Young | 263 |
| Jin | 263 |
| Cytokine | 263 |
| Database | 262 |
| Pan | 262 |
| São | 262 |
| T2DM | 262 |
| mm | 262 |
| zu | 261 |
| Baricitinib | 261 |
| número | 260 |
| Retrospective | 260 |
| Martin | 260 |
| Factor | 260 |
| manejo | 259 |
| bei | 259 |
| Resource | 259 |
| Pathogenesis | 259 |
| LTC | 259 |
| LOS | 259 |
| Initial | 259 |
| Dental | 258 |
| Welfare | 258 |
| SE | 258 |
| Obesity | 257 |
| Fear | 257 |
| ® | 257 |
| ivermectin | 257 |
| rd | 257 |
| Indonesia | 256 |
| IR | 256 |
| Eur | 256 |
| PAI-1 | 255 |
| Communication | 255 |
| Interferon | 254 |
| Park | 253 |
| Ghana | 253 |
| werden | 253 |
| Viruses | 253 |
| miRNAs | 253 |
| Dysregulation | 252 |
| Feb | 252 |
| KCDC | 252 |
| ICH | 252 |
| RCTs | 252 |
| Philippines | 252 |
| TCR | 252 |
| Zheng | 252 |
| lymphocytopenia | 251 |
| NYC | 251 |
| Ma | 250 |
| Ali | 250 |
| mTOR | 249 |
| den | 249 |
| YouTube | 249 |
| Neck | 249 |
| Models | 249 |
| Inactive | 249 |
| síntomas | 248 |
| Saharan | 247 |
| PaO | 247 |
| Immunology | 247 |
| EUA | 247 |
| Correlation | 247 |
| Recovery | 247 |
| Seoul | 246 |
| Modeling | 246 |
| Media | 246 |
| CS | 246 |
| Host | 245 |
| Gao | 245 |
| Home | 244 |
| ADE | 244 |
| Excel | 244 |
| Medicaid | 244 |
| hasta | 244 |
| Ray | 243 |
| Python | 243 |
| Prime | 243 |
| Lockdown | 243 |
| HD | 243 |
| Federation | 243 |
| pueden | 242 |
| baricitinib | 242 |
| MCP-1 | 242 |
| Coagulopathy | 242 |
| Adult | 242 |
| Tables | 241 |
| AP | 241 |
| CPR | 241 |
| Great | 241 |
| fue | 241 |
| Yin | 241 |
| methylprednisolone | 241 |
| tele | 240 |
| Strategies | 240 |
| Coronavirus-2 | 240 |
| CMS | 240 |
| Bluetooth | 240 |
| Th17 | 239 |
| S4 | 239 |
| Norway | 239 |
| NSAIDs | 239 |
| CTPA | 239 |
| Han | 238 |
| IL-4 | 238 |
| Berlin | 238 |
| Miller | 238 |
| Z | 238 |
| einer | 238 |
| Pre | 237 |
| Guide | 237 |
| Dong | 237 |
| Ahmed | 237 |
| tPA | 236 |
| respiratoria | 236 |
| committee | 236 |
| W | 236 |
| MR | 236 |
| Chang | 236 |
| MI | 235 |
| Dimer | 235 |
| Position | 234 |
| EDs | 234 |
| Diabetes | 234 |
| https | 234 |
| EN | 234 |
| Greece | 234 |
| ct | 233 |
| Section | 233 |
| SSA | 233 |
| Liang | 233 |
| Flu | 233 |
| ESR | 233 |
| IL-18 | 232 |
| Di | 232 |
| Contact | 232 |
| Inflammatory | 231 |
| Inhibitor | 231 |
| corona | 231 |
| son | 231 |
| ingreso | 230 |
| https://doi.org/10.1101 | 230 |
| TGF | 230 |
| Standard | 230 |
| Massachusetts | 230 |
| Florida | 230 |
| Behavior | 230 |
| Scholar | 229 |
| PPV | 229 |
| Lymphopenia | 229 |
| Disorders | 229 |
| CRRT | 229 |
| Critically | 228 |
| Barcelona | 228 |
| Letter | 228 |
| Korean | 228 |
| CAD | 227 |
| BAME | 227 |
| Law | 227 |
| Gilead | 227 |
| Software | 226 |
| Environ | 226 |
| auf | 226 |
| Tan | 226 |
| Peter | 225 |
| IES | 225 |
| Epub | 225 |
| Affairs | 225 |
| Surface | 225 |
| Library | 224 |
| Allergy | 224 |
| Ann | 224 |
| TF | 224 |
| μg | 224 |
| Yao | 223 |
| Quarantine | 223 |
| Electronic | 223 |
| DPP4 | 223 |
| Bureau | 223 |
| metformin | 223 |
| MAPK | 222 |
| Function | 222 |
| Disorder | 222 |
| Action | 222 |
| Por | 221 |
| Division | 221 |
| max | 221 |
| Literature | 220 |
| Special | 220 |
| Ethical | 220 |
| Chongqing | 220 |
| Burden | 220 |
| national | 219 |
| evidencia | 219 |
| durante | 219 |
| data | 219 |
| NPIs | 219 |
| Colombia | 219 |
| Advisory | 219 |
| Comparative | 218 |
| Fund | 218 |
| Olfactory | 218 |
| Rheumatology | 218 |
| Stem | 218 |
| Ultrasound | 217 |
| Transplantation | 217 |
| OCD | 217 |
| Myocardial | 217 |
| MHC | 217 |
| Infected | 217 |
| Guangzhou | 217 |
| Crohn | 217 |
| Antibodies | 217 |
| alta | 216 |
| PAPR | 216 |
| Fang | 215 |
| IL-7 | 215 |
| Single | 215 |
| O. | 215 |
| dl | 215 |
| ne | 214 |
| department | 214 |
| así | 214 |
| Yi | 214 |
| Professor | 214 |
| Peng | 214 |
| Multicenter | 214 |
| España | 214 |
| Comorbidities | 214 |
| CLD | 214 |
| NPI | 213 |
| Brown | 213 |
| Emerg | 213 |
| Work | 213 |
| PDB | 213 |
| Scotland | 213 |
| été | 213 |
| range | 212 |
| edad | 212 |
| Term | 212 |
| Renal | 212 |
| LSTM | 212 |
| Chain | 212 |
| HU | 211 |
| Columbia | 211 |
| Authority | 211 |
| Market | 211 |
| Resources | 211 |
| Primary | 211 |
| Sharma | 210 |
| Pediatr | 210 |
| Mobile | 210 |
| Inhibition | 210 |
| BNP | 210 |
| 3CL | 210 |
| IP-10 | 209 |
| Cells | 209 |
| clínica | 209 |
| Rev | 209 |
| Sleep | 209 |
| Disaster | 208 |
| Forum | 208 |
| James | 208 |
| Immunity | 208 |
| Wallis | 208 |
| P<0.001 | 208 |
| grupo | 208 |
| recomendaciones | 208 |
| años | 207 |
| Veneto | 207 |
| PCA | 207 |
| ILI | 207 |
| Handbook | 207 |
| Future | 207 |
| Poland | 206 |
| ATP | 206 |
| Map | 206 |
| Physical | 206 |
| Khan | 206 |
| Strategy | 206 |
| TLR4 | 206 |
| mmol | 206 |
| otros | 206 |
| Isolation | 205 |
| Bayesian | 205 |
| a1111111111 | 205 |
| Labor | 205 |
| Monte | 205 |
| social | 204 |
| il | 204 |
| enzyme-2 | 204 |
| Lai | 204 |
| Death | 204 |
| BC | 204 |
| Andrea | 204 |
| middle | 204 |
| personal | 203 |
| Short | 203 |
| PLWH | 203 |
| Occupational | 203 |
| Physicians | 202 |
| HCoV-229E | 202 |
| Dataset | 202 |
| Spring | 202 |
| Taxonomy | 202 |
| Incubation | 201 |
| APACHE | 201 |
| Gupta | 201 |
| Embase | 201 |
| Patienten | 201 |
| S5 | 201 |
| par | 201 |
| wuhan | 201 |
| IL-6R | 200 |
| H7N9 | 200 |
| Countries | 200 |
| Concern | 200 |
| Orthopaedic | 199 |
| Executive | 199 |
| House | 199 |
| Ottawa | 199 |
| resultados | 199 |
| SpO | 199 |
| Troponin | 199 |
| Related | 199 |
| todos | 198 |
| di | 198 |
| Si | 198 |
| Kruskal | 198 |
| Antonio | 198 |
| Andrew | 198 |
| Abbott | 198 |
| SAR | 197 |
| DAD | 197 |
| Jiang | 197 |
| Neurological | 197 |
| Staphylococcus | 197 |
| War | 197 |
| Wong | 197 |
| chez | 197 |
| si | 197 |
| Urban | 196 |
| Training | 196 |
| Huanan | 196 |
| σ | 195 |
| Vascular | 195 |
| Universal | 195 |
| Units | 195 |
| Mesenchymal | 195 |
| Francisco | 195 |
| Eastern | 194 |
| Mission | 194 |
| CTA | 194 |
| Incidence | 194 |
| Z. | 194 |
| Predictors | 194 |
| Rights | 194 |
| endosomal | 194 |
| Treg | 194 |
| Mobility | 193 |
| Jun | 193 |
| Corporation | 193 |
| Anosmia | 193 |
| Modelling | 193 |
| tiempo | 192 |
| Trade | 192 |
| Period | 192 |
| ECDC | 192 |
| Convolutional | 192 |
| BD | 191 |
| Janus | 191 |
| Barr | 191 |
| Responses | 191 |
| Number | 191 |
| Southern | 191 |
| dos | 190 |
| NIC | 190 |
| HCPs | 190 |
| Chile | 190 |
| Validation | 189 |
| Comprehensive | 189 |
| Resilience | 189 |
| Mass | 189 |
| anti | 189 |
| atención | 189 |
| fueron | 189 |
| Collaborative | 188 |
| BACKGROUND | 188 |
| Business | 188 |
| CD14 | 188 |
| protección | 188 |
| Overview | 188 |
| darunavir | 188 |
| X. | 188 |
| Tomography | 187 |
| Silva | 187 |
| SUD | 187 |
| RRT | 187 |
| CXCL10 | 187 |
| Anakinra | 187 |
| Airway | 187 |
| AIS | 187 |
| Box | 186 |
| Anna | 186 |
| p<0.01 | 186 |
| ESC | 186 |
| AF | 185 |
| Australian | 185 |
| Brief | 185 |
| Hospitals | 185 |
| IL6 | 185 |
| Integrated | 185 |
| Interaction | 185 |
| JAMA | 185 |
| Mark | 185 |
| L1 | 185 |
| pero | 185 |
| OHCA | 185 |
| review | 185 |
| protein | 185 |
| Zoom | 185 |
| SA | 185 |
| Patel | 185 |
| nivel | 184 |
| Marco | 184 |
| MEDLINE | 184 |
| Luo | 184 |
| Jones | 184 |
| BBB | 184 |
| Zhong | 184 |
| Comparison | 183 |
| Baseline | 183 |
| Song | 183 |
| Qi | 183 |
| mecánica | 183 |
| Juan | 182 |
| Alliance | 182 |
| Angeles | 182 |
| ICI | 182 |
| Imperial | 182 |
| Press | 182 |
| Peru | 182 |
| SP | 182 |
| Stability | 182 |
| cTnI | 182 |
| chi | 182 |
| Latinx | 181 |
| Code | 181 |
| George | 181 |
| Gy | 181 |
| Richard | 181 |
| TNFα | 181 |
| appendix | 181 |
| Exposure | 180 |
| Boston | 180 |
| Carlos | 180 |
| Dashboard | 180 |
| thromboprophylaxis | 180 |
| Figs | 180 |
| Xie | 180 |
| Jean | 180 |
| Su | 179 |
| S6 | 179 |
| Red | 179 |
| Preferred | 179 |
| Feng | 179 |
| Fc | 179 |
| Diagnostics | 179 |
| AngII | 179 |
| EMR | 178 |
| ACEi | 178 |
| AT1R | 178 |
| Delivery | 178 |
| auch | 178 |
| Leone | 178 |
| OECD | 178 |
| Trauma | 178 |
| Grant | 177 |
| Genomic | 177 |
| Civil | 177 |
| Text | 177 |
| Brescia | 177 |
| ACC | 177 |
| MT | 177 |
| Il | 177 |
| neurosurgery | 177 |
| Mediterranean | 177 |
| Polymerase | 177 |
| Preliminary | 177 |
| Salud | 177 |
| d'une | 177 |
| marzo | 177 |
| Multiple | 177 |
| Hepatitis | 176 |
| Betacoronavirus | 176 |
| Cognitive | 176 |
| HCC | 176 |
| https:// | 176 |
| ORF1ab | 176 |
| qRT | 176 |
| rRT | 176 |
| thrombi | 176 |
| Growth | 175 |
| A1 | 175 |
| Apple | 175 |
| Big | 175 |
| District | 175 |
| tanto | 175 |
| IL-12 | 175 |
| Sierra | 175 |
| Therapeutics | 175 |
| cuidados | 175 |
| Facility | 174 |
| Language | 174 |
| GraphPad | 174 |
| HIPAA | 174 |
| ICMJE | 174 |
| ISTH | 174 |
| methotrexate | 174 |
| Paper | 174 |
| covid | 174 |
| desde | 174 |
| oseltamivir | 174 |
| Screening | 174 |
| Yuan | 173 |
| Academic | 173 |
| Corticosteroid | 173 |
| Internal | 173 |
| Multisystem | 173 |
| SEM | 173 |
| das | 173 |
| día | 173 |
| est | 173 |
| interferon | 173 |
| neurotropic | 173 |
| solo | 173 |
| Blockers | 172 |
| Ct | 172 |
| GPS | 172 |
| Medicines | 172 |
| Interventional | 172 |
| Package | 172 |
| VEGF | 172 |
| oder | 172 |
| Performance | 172 |
| SI | 171 |
| AR | 171 |
| CD16 | 171 |
| CoV-2-specific | 171 |
| Fever | 171 |
| Intervention | 171 |
| Items | 171 |
| MB | 171 |
| Neurologic | 171 |
| Simulation | 171 |
| Taylor | 171 |
| clínico | 171 |
| coronavirus-2 | 171 |
| patient | 171 |
| realizar | 171 |
| tipo | 171 |
| © | 171 |
| Neurology | 170 |
| CCL2 | 170 |
| GS-5734 | 170 |
| M1 | 170 |
| Manifestations | 170 |
| Asians | 170 |
| Pregnancy | 170 |
| Sichuan | 170 |
| Year | 170 |
| también | 170 |
| Radiological | 170 |
| PICU | 169 |
| AE | 169 |
| BBC | 169 |
| Bergamo | 169 |
| Fleischner | 169 |
| Houston | 169 |
| PUI | 169 |
| Stage | 169 |
| UFH | 169 |
| pandémie | 169 |
| seq | 169 |
| sospecha | 169 |
| PBS | 168 |
| GC | 168 |
| Innovation | 168 |
| Ventilation | 168 |
| PP | 168 |
| p<0.0001 | 168 |
| ≥ | 167 |
| ml | 167 |
| Willebrand | 167 |
| Survival | 167 |
| Staff | 167 |
| Gastroenterology | 167 |
| Finland | 167 |
| Epstein | 167 |
| Release | 166 |
| Alexander | 166 |
| Collaboration | 166 |
| Hui | 166 |
| Orleans | 166 |
| Triage | 166 |
| Ye | 166 |
| colchicine | 166 |
| https://doi.org/10 | 166 |
| Un | 166 |
| sus | 165 |
| según | 165 |
| pulmonar | 165 |
| análisis | 165 |
| Search | 165 |
| Mechanism | 165 |
| FFP2 | 165 |
| Energy | 165 |
| FC | 164 |
| Mayo | 164 |
| Mao | 164 |
| Theory | 164 |
| Novartis | 164 |
| Radiol | 164 |
| Sepsis | 164 |
| Francesco | 163 |
| Co. | 163 |
| Comorbidity | 163 |
| Conference | 163 |
| Controlled | 163 |
| 2D | 163 |
| GA | 163 |
| Ho | 163 |
| Laura | 163 |
| Respir | 163 |
| muestra | 163 |
| Genome | 162 |
| Amazon | 162 |
| Brazilian | 162 |
| Diego | 162 |
| EMA | 162 |
| Era | 162 |
| García | 162 |
| deben | 162 |
| Hypertension | 162 |
| Pathology | 162 |
| Pharmaceutical | 162 |
| Protease | 162 |
| Sustainable | 162 |
| OS | 162 |
| Immunol | 161 |
| CCP | 161 |
| CE | 161 |
| Du | 161 |
| IFR | 161 |
| Illinois | 161 |
| May. | 161 |
| Load | 161 |
| Newcastle | 161 |
| Prevalence | 161 |
| prise | 161 |
| salud | 161 |
| Carolina | 160 |
| Charlson | 160 |
| IPV | 160 |
| AB | 160 |
| FFP3 | 160 |
| Departments | 160 |
| NAC | 160 |
| 160 | |
| Practices | 160 |
| Psychiatric | 160 |
| SSRN | 160 |
| Platform | 160 |
| Ltd. | 159 |
| Armonk | 159 |
| Es | 159 |
| Faculty | 159 |
| Authorization | 159 |
| Regulation | 159 |
| Reports | 159 |
| Sex | 159 |
| Total | 159 |
| thromboplastin | 158 |
| nucleocapsid | 158 |
| UC | 158 |
| Perceived | 158 |
| PET | 158 |
| Macrophage | 158 |
| GIS | 158 |
| 3a | 158 |
| Manual | 157 |
| Breast | 157 |
| Brooks | 157 |
| Extended | 157 |
| Epidemiologic | 157 |
| Wan | 157 |
| Xue | 157 |
| ya | 157 |
| Zn | 157 |
| novo | 157 |
| sont | 156 |
| Wen | 156 |
| Solidarity | 156 |
| POCUS | 156 |
| NICU | 156 |
| Markov | 156 |
| LA | 156 |
| Delphi | 156 |
| AZ | 156 |
| ACR | 156 |
| AMI | 155 |
| Endoscopy | 155 |
| Nurses | 155 |
| cada | 154 |
| Traditional | 154 |
| Thromboembolic | 154 |
| Third | 154 |
| Supply | 154 |
| Presymptomatic | 154 |
| Maharashtra | 154 |
| Insurance | 154 |
| Current | 154 |
| A2 | 153 |
| Adam | 153 |
| GWAS | 153 |
| Cryo | 153 |
| Fangcang | 153 |
| Financial | 153 |
| Breakthrough | 153 |
| IT | 153 |
| neutrophilia | 153 |
| pg | 153 |
| OSA | 153 |
| Rome | 153 |
| Pharmacologic | 153 |
| HP | 152 |
| Barre | 152 |
| GP | 152 |
| Giuseppe | 152 |
| Green | 152 |
| AUROC | 152 |
| Mathematical | 152 |
| Paolo | 152 |
| REDCap | 152 |
| Thrombocytopenia | 152 |
| NPV | 152 |
| NPS | 151 |
| Country | 151 |
| Detroit | 151 |
| Industry | 151 |
| José | 151 |
| PBMC | 151 |
| Value | 151 |
| ρ | 151 |
| sich | 151 |
| Inception | 150 |
| APS | 150 |
| Alberta | 150 |
| Christopher | 150 |
| Giovanni | 150 |
| Heparin | 150 |
| ID-19 | 150 |
| MOH | 150 |
| Step | 150 |
| TLR | 150 |
| Toll | 150 |
| heparin | 150 |
| sido | 150 |
| R(t | 150 |
| Structural | 149 |
| INR | 149 |
| Iceland | 149 |
| Register | 149 |
| Therapeutic | 149 |
| lymphohistiocytosis | 149 |
| qui | 149 |
| Multi | 148 |
| BAL | 148 |
| CMV | 148 |
| Climate | 148 |
| DT | 148 |
| German | 148 |
| Hg | 148 |
| Insomnia | 148 |
| Jersey | 148 |
| Venous | 148 |
| Northeast | 148 |
| Ohio | 148 |
| Otolaryngology | 148 |
| RD | 148 |
| Second | 148 |
| Xia | 148 |
| menor | 148 |
| ms | 148 |
| Consent | 147 |
| RSNA | 147 |
| HC | 147 |
| EVD | 147 |
| Technical | 147 |
| momento | 147 |
| recursos | 147 |
| board | 147 |
| Corticosteroids | 146 |
| Anesthesia | 146 |
| Asthma | 146 |
| Author | 146 |
| Bayes | 146 |
| CD147 | 146 |
| Extracellular | 146 |
| IVIg | 146 |
| Providers | 146 |
| Racial | 146 |
| Smart | 146 |
| pruebas | 146 |
| Lei | 145 |
| Co | 145 |
| Core | 145 |
| Gender | 145 |
| ICS | 145 |
| Joseph | 145 |
| Ying | 145 |
| PS | 145 |
| Pharmacy | 145 |
| Rates | 145 |
| SARI | 145 |
| servicios | 145 |
| Morocco | 144 |
| CHD | 144 |
| COVID-19-infected | 144 |
| CRC | 144 |
| CV | 144 |
| Colorado | 144 |
| SMD | 144 |
| Prospective | 144 |
| Virology | 144 |
| pro | 144 |
| profesionales | 144 |
| rt | 144 |
| Rehabilitation | 143 |
| Aldosterone | 143 |
| Biological | 143 |
| COVID-19-related | 143 |
| Definition | 143 |
| GitHub | 143 |
| IMF | 143 |
| Neurosurgery | 143 |
| Regulations | 143 |
| Reverse | 143 |
| Shen | 143 |
| Southeast | 143 |
| Status | 143 |
| Tissue | 143 |
| Tracker | 143 |
| aguda | 143 |
| kw | 143 |
| nicht | 143 |
| niveles | 143 |
| Regression | 142 |
| Considerations | 142 |
| DASS | 142 |
| EP | 142 |
| Fan | 142 |
| TX | 142 |
| neuro | 142 |
| chemoattractant | 142 |
| miRNA | 142 |
| Wave | 142 |
| Disparities | 141 |
| APTT | 141 |
| Cai | 141 |
| Animal | 141 |
| Measures | 141 |
| nan | 141 |
| Thromboembolism | 141 |
| org/ | 141 |
| Elective | 141 |
| Henry | 140 |
| SDRA | 140 |
| Positive | 140 |
| Nguyen | 140 |
| Chief | 140 |
| Entry | 140 |
| BP | 140 |
| Asymptomatic | 140 |
| TTE | 140 |
| Scott | 140 |
| Hispanics | 140 |
| Temporal | 140 |
| VT | 140 |
| administration | 140 |
| ces | 140 |
| diferentes | 140 |
| información | 140 |
| owner(s | 140 |
| zur | 140 |
| ∈ | 140 |
| Tian | 140 |
| Nationwide | 139 |
| ADAM17 | 139 |
| 139 | |
| Assay | 139 |
| Wilson | 139 |
| hyperinflammatory | 139 |
| urology | 139 |
| cuenta | 139 |
| Inpatient | 138 |
| Britain | 138 |
| C3 | 138 |
| Complex | 138 |
| Facilities | 138 |
| Generalized | 138 |
| Perspective | 138 |
| PLpro | 138 |
| Qin | 138 |
| Radiation | 138 |
| Travel | 138 |
| Xiang | 138 |
| pour | 138 |
| Qiu | 137 |
| Oral | 137 |
| VID-19 | 137 |
| Healthy | 137 |
| ESRD | 137 |
| CSI | 137 |
| Rio | 137 |
| Local | 137 |
| VIII | 137 |
| bioRxiv | 137 |
| bronchogram | 137 |
| menos | 137 |
| mmHg | 137 |
| realización | 137 |
| Williams | 137 |
| Complement | 136 |
| Affiliated | 136 |
| Agriculture | 136 |
| Anderson | 136 |
| Ang-(1 | 136 |
| Biomedical | 136 |
| CORD-19 | 136 |
| CTC | 136 |
| HEPA | 136 |
| Machine | 136 |
| Malaria | 136 |
| Nowcasting | 136 |
| Prism | 136 |
| Vienna | 136 |
| neumonía | 136 |
| time | 136 |
| Psychometric | 135 |
| Algeria | 135 |
| Calmette | 135 |
| Mas | 135 |
| Origin | 135 |
| Presenting | 135 |
| Planning | 135 |
| Seafood | 135 |
| seguridad | 135 |
| Tool | 135 |
| b. | 135 |
| lung | 135 |
| microangiopathy | 135 |
| Station | 135 |
| Longitudinal | 134 |
| AC | 134 |
| DKA | 134 |
| Evidence | 134 |
| Garcia | 134 |
| Income | 134 |
| LD | 134 |
| Guinea | 134 |
| Mechanical | 134 |
| Microbiology | 134 |
| PR | 134 |
| STATA | 134 |
| T2 | 134 |
| VV | 134 |
| Meng | 134 |
| Common | 133 |
| None | 133 |
| Effects | 133 |
| Editorial | 133 |
| Cov2 | 133 |
| BTK | 133 |
| CSSE | 133 |
| COV2 | 133 |
| CD | 133 |
| Approval | 133 |
| Analyses | 133 |
| Household | 133 |
| Egger | 133 |
| PHEIC | 133 |
| Treatments | 133 |
| Palliative | 133 |
| trabajo | 133 |
| ti | 133 |
| situación | 133 |
| William | 133 |
| arthroplasty | 133 |
| Susceptibility | 133 |
| SDG | 133 |
| Reduction | 133 |
| Recognition | 133 |
| Profile | 133 |
| HPA | 132 |
| AL | 132 |
| Ace2 | 132 |
| Bio | 132 |
| CIs | 132 |
| Decision | 132 |
| Sinai | 132 |
| Ivermectin | 132 |
| Louisiana | 132 |
| MCO | 132 |
| Supplement | 132 |
| actividad | 132 |
| ISI | 131 |
| BK | 131 |
| Body | 131 |
| Cellular | 131 |
| E2 | 131 |
| Economics | 131 |
| Dysfunction | 131 |
| Pradesh | 131 |
| Victoria | 131 |
| Vitro | 131 |
| mayores | 131 |
| revisión | 131 |
| Urology | 131 |
| Programme | 130 |
| EBV | 130 |
| EMBASE | 130 |
| HCoVs | 130 |
| Jiangsu | 130 |
| Matthew | 130 |
| PCI | 130 |
| Para | 130 |
| Mohammad | 130 |
| SB | 130 |
| Stockholm | 130 |
| TLR7 | 130 |
| VWF | 130 |
| complicaciones | 130 |
| d. | 130 |
| dosis | 130 |
| mycophenolate | 130 |
| Senegal | 130 |
| Islam | 129 |
| Conditions | 129 |
| Infarction | 129 |
| NIHR | 129 |
| Medline | 129 |
| Zeng | 129 |
| clínicos | 129 |
| ISARIC | 128 |
| Broad | 128 |
| CCC | 128 |
| CR | 128 |
| Deng | 128 |
| Gautret | 128 |
| coronaviruses | 128 |
| Insights | 128 |
| NS | 128 |
| Pediatrics | 128 |
| Sub | 128 |
| Tuberculosis | 128 |
| Major | 128 |
| Perspectives | 127 |
| Collection | 127 |
| Free | 127 |
| Henan | 127 |
| María | 127 |
| dass | 127 |
| debido | 127 |
| estos | 127 |
| mediante | 127 |
| prednisone | 127 |
| traitement | 127 |
| GB | 126 |
| Advanced | 126 |
| Binding | 126 |
| CFS | 126 |
| Cytokines | 126 |
| Zhonghua | 126 |
| Involvement | 126 |
| Oseltamivir | 126 |
| Symptom | 126 |
| tasa | 126 |
| Preventive | 125 |
| CCI | 125 |
| Cluster | 125 |
| Golgi | 125 |
| HS | 125 |
| IPA | 125 |
| Loneliness | 125 |
| Mar | 125 |
| PK | 125 |
| Personnel | 125 |
| Psychology | 125 |
| Progression | 125 |
| Secretary | 125 |
| þ | 125 |
| arbidol | 125 |
| Tokyo | 125 |
| parainfluenza | 125 |
| Real | 125 |
| Random | 125 |
| RDW | 125 |
| Mount | 124 |
| -Preliminary | 124 |
| Arizona | 124 |
| Behavioral | 124 |
| Bonferroni | 124 |
| Ecuador | 124 |
| GSH | 124 |
| Inventory | 124 |
| Quantitative | 124 |
| Sanofi | 124 |
| Technologies | 124 |
| Web | 124 |
| ruxolitinib | 124 |
| tacrolimus | 124 |
| trans | 124 |
| 124 | |
| PHE | 123 |
| Autopsy | 123 |
| Disease-2019 | 123 |
| Elevation | 123 |
| JACC | 123 |
| Loss | 123 |
| MG | 123 |
| ≈ | 123 |
| POC | 123 |
| necesario | 123 |
| protein-1 | 123 |
| selectin | 123 |
| ε | 123 |
| � | 123 |
| Relation | 123 |
| HADS | 122 |
| Jose | 122 |
| Harris | 122 |
| HTN | 122 |
| Change | 122 |
| FiO | 122 |
| Event | 122 |
| Colchicine | 122 |
| Mumbai | 122 |
| Key | 122 |
| BCT | 122 |
| NH | 122 |
| Wenzhou | 122 |
| respiratorio | 122 |
| contra | 122 |
| aux | 122 |
| square | 122 |
| Upper | 122 |
| St. | 122 |
| Shah | 122 |
| Sarah | 122 |
| SF | 122 |
| FPV | 121 |
| -p | 121 |
| App | 121 |
| BHB | 121 |
| Burnout | 121 |
| CD19 | 121 |
| COVID-19-induced | 121 |
| Congress | 121 |
| Excellence | 121 |
| MedDiet | 121 |
| Inc | 121 |
| STROBE | 121 |
| Square | 121 |
| Storm | 121 |
| Tehran | 121 |
| airways | 121 |
| personas | 121 |
| proBNP | 121 |
| Nacional | 121 |
| Expression | 120 |
| Generation | 120 |
| Forecasting | 120 |
| File | 120 |
| MCP1 | 120 |
| CO2 | 120 |
| AIC | 120 |
| AA | 120 |
| Iraq | 120 |
| Pfizer | 120 |
| Mr. | 120 |
| Standards | 120 |
| NAbs | 120 |
| Xa | 120 |
| Veterans | 120 |
| criterios | 120 |
| ReLU | 120 |
| población | 120 |
| NOS | 120 |
| NADPH | 119 |
| Applications | 119 |
| CMR | 119 |
| D3 | 119 |
| EPI | 119 |
| Frailty | 119 |
| Glasgow | 119 |
| KAP | 119 |
| Independent | 119 |
| Ng | 119 |
| OpenSAFELY | 119 |
| Sect | 119 |
| WM | 119 |
| group | 119 |
| respuesta | 119 |
| scan | 119 |
| simplex | 119 |
| Georgia | 118 |
| Jonathan | 118 |
| Jing | 118 |
| Ji | 118 |
| HbA1c | 118 |
| Alberto | 118 |
| GO | 118 |
| DE | 118 |
| COVID-19-positive | 118 |
| Ling | 118 |
| AGP | 118 |
| Labour | 118 |
| Sri | 118 |
| Mohamed | 118 |
| Pubmed | 118 |
| RH | 118 |
| Settings | 118 |
| sciences | 118 |
| Transport | 118 |
| alto | 118 |
| ante | 118 |
| clínicas | 118 |
| journal | 118 |
| myalgias | 118 |
| Nanjing | 118 |
| NCP | 117 |
| Benjamin | 117 |
| Edition | 117 |
| Mycobacterium | 117 |
| Shapiro | 117 |
| Presentation | 117 |
| centros | 117 |
| seguimiento | 117 |
| AH | 116 |
| CBC | 116 |
| Island | 116 |
| Cameroon | 116 |
| Crit | 116 |
| Ddimer | 116 |
| Emilia | 116 |
| Essential | 116 |
| Ventilator | 116 |
| KDIGO | 116 |
| Ribavirin | 116 |
| Sequential | 116 |
| StataCorp | 116 |
| Thrombotic | 116 |
| famotidine | 116 |
| kappaB | 116 |
| LP | 116 |
| COVID-19-associated | 115 |
| FDR | 115 |
| Choi | 115 |
| Cardiol | 115 |
| AHA | 115 |
| Bai | 115 |
| BALB | 115 |
| Kuwait | 115 |
| = | 115 |
| ICT | 115 |
| AMCI | 115 |
| Lab | 115 |
| Sectional | 115 |
| MPs | 115 |
| evolución | 115 |
| Vaccines | 115 |
| Thermo | 115 |
| Zhongnan | 115 |
| Prof. | 115 |
| Pierre | 115 |
| Pharma | 115 |
| OA | 115 |
| Philadelphia | 114 |
| Atlas | 114 |
| Christian | 114 |
| ITU | 114 |
| Implications | 114 |
| Janssen | 114 |
| Methodology | 114 |
| Ophthalmology | 114 |
| Target | 114 |
| Seroprevalence | 114 |
| ULN | 114 |
| elevation | 114 |
| mesylate | 114 |
| non | 114 |
| pronóstico | 114 |
| tiene | 114 |
| JAK2 | 113 |
| Acad | 113 |
| Brasil | 113 |
| Capsule | 113 |
| Charles | 113 |
| CoVID-19 | 113 |
| Connecticut | 113 |
| Das | 113 |
| Briefing | 113 |
| Min | 113 |
| Tao | 113 |
| caso | 113 |
| antes | 113 |
| pp | 113 |
| Muhammad | 113 |
| SOFA | 113 |
| Provincial | 113 |
| Qatar | 113 |
| Induced | 112 |
| Bias | 112 |
| Combination | 112 |
| Cui | 112 |
| Cureus | 112 |
| Defense | 112 |
| Dermatology | 112 |
| ESKD | 112 |
| Elizabeth | 112 |
| Feasibility | 112 |
| Fu | 112 |
| Hua | 112 |
| BS | 112 |
| López | 112 |
| Sara | 112 |
| ∞ | 112 |
| M2 | 112 |
| respiratoire | 112 |
| frente | 112 |
| study | 112 |
| Pathway | 112 |
| PEEP | 112 |
| Niger | 112 |
| N-95 | 112 |
| Materials | 112 |
| Akt | 111 |
| Americas | 111 |
| BERT | 111 |
| CAS | 111 |
| Distribution | 111 |
| Española | 111 |
| Genetic | 111 |
| Induction | 111 |
| Interval | 111 |
| LVEF | 111 |
| Luis | 111 |
| TTS | 111 |
| Multidisciplinary | 111 |
| síndrome | 111 |
| novel | 111 |
| Vulnerability | 111 |
| Russell | 111 |
| Qualtrics | 111 |
| Procalcitonin | 111 |
| Optimal | 111 |
| Understanding | 110 |
| Congo | 110 |
| Harvard | 110 |
| Hunan | 110 |
| Jeffrey | 110 |
| Jia | 110 |
| KRT | 110 |
| KSA | 110 |
| Leung | 110 |
| Method | 110 |
| Regulatory | 110 |
| H3 | 110 |
| Xiong | 110 |
| View | 110 |
| sind | 110 |
| als | 110 |
| μM | 110 |
| vía | 110 |
| transmisión | 110 |
| tras | 110 |
| sanitario | 110 |
| microthrombi | 110 |
| herpes | 110 |
| hepcidin | 110 |
| angiotensin | 110 |
| PN | 109 |
| CAM | 109 |
| Complications | 109 |
| Greater | 109 |
| HNC | 109 |
| Jakarta | 109 |
| Objective | 109 |
| Pain | 109 |
| SES | 109 |
| Spatial | 109 |
| enfermedades | 109 |
| hypogeusia | 109 |
| manera | 109 |
| SAH | 109 |
| parte | 109 |
| NHC | 108 |
| Drugs | 108 |
| Italia | 108 |
| ICD-10 | 108 |
| Gastrointestinal | 108 |
| G1 | 108 |
| AZM | 108 |
| Computer | 108 |
| Algorithm | 108 |
| AU | 108 |
| AS | 108 |
| Lagos | 108 |
| Yong | 108 |
| PTC299 | 108 |
| bajo | 108 |
| Power | 108 |
| nos | 108 |
| http:// | 108 |
| e. | 108 |
| equipo | 108 |
| Worldometer | 108 |
| Vincent | 108 |
| Saúde | 108 |
| RI | 108 |
| Eric | 107 |
| Luca | 107 |
| IA | 107 |
| Hypercoagulability | 107 |
| Hoffmann | 107 |
| Governor | 107 |
| Anne | 107 |
| Corp. | 107 |
| Chin | 107 |
| ChAdOx1 | 107 |
| BMC | 107 |
| AAT | 107 |
| Mainland | 107 |
| Ming | 107 |
| Municipal | 107 |
| Siemens | 107 |
| OP | 107 |
| necesidad | 107 |
| intensivos | 107 |
| VitD | 107 |
| Une | 107 |
| Video | 107 |
| Santos | 107 |
| Sample | 107 |
| RBC | 107 |
| RADS | 107 |
| PWUD | 107 |
| PROSPERO | 107 |
| PLoS | 106 |
| Company | 106 |
| Cristina | 106 |
| Furin | 106 |
| Immediate | 106 |
| Microbiol | 106 |
| Teams | 106 |
| Umifenovir | 106 |
| Wilk | 106 |
| doit | 106 |
| muy | 106 |
| Tertiary | 106 |
| NLP | 105 |
| CPT | 105 |
| Ltd | 105 |
| Lebanon | 105 |
| Economy | 105 |
| Chemical | 105 |
| Ag | 105 |
| CM | 105 |
| Alcohol | 105 |